Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: In vitro study

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 20, Issue 9, 2007, Pages 695-701

  Al Saleh, Eyad ^a   Nandakumaran, Moorkath ^a   Al Rashdan, Ibrahim ^a   Al Harmi, Jehad ^a   Al Shammari, Majed ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Anti cancer drugs; Antipyrine; Carboplatin; Human placental perfusion; In vitro; Maternal fetal exchange

Indexed keywords

CARBOPLATIN; PHENAZONE; SODIUM CHLORIDE;

ADULT; AREA UNDER THE CURVE; ARTERIAL CIRCULATION; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CONTROLLED STUDY; DILUTION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG TISSUE LEVEL; EFFLUENT; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; NEWBORN; PLACENTA PERFUSION; PLACENTAL TRANSFER; PRIORITY JOURNAL; PUERPERIUM; SPECTROPHOTOMETRY; STUDENT T TEST; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE CULTURE; VEIN;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ANTIPYRINE; BIOLOGICAL AVAILABILITY; CARBOPLATIN; FEMALE; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; METABOLIC CLEARANCE RATE; PERFUSION; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC;

EID: 34547889529     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050701437302     Document Type: Article

References (46)

1. Jamieson ER, Lippard SJ. Structure, recognition and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467-2498.
2. Reedijk J. New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA. Proc Natl Acad Sci USA 2003;100:3611-3616.
3. Hogberg T, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001;40:340-360.
4. Alberts DS, Dorr RT. New perspectives on an old friend: Optimizing carboplatin for the treatment of solid tumors. Oncologist 1998;3:1-36.
5. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-422.
6. Perez EA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist 2004;6:518-527.
7. Kolaric K, Vukas D. Carboplatin activity in untreated metastatic breast cancer patients - results of a phase II study. Cancer Chemother Pharmacol 1991;27:409-412.
8. Young RC. Gynecologic malignancies. Cancer Chemother Biol Response Modif 1987;9:303-337.
9. De Andres Basauri L, Lopez Pousa A, Alba E, Sampedro F. Carboplatin, an active drug in advanced head and neck cancer. Cancer Treat Rep 1986;70:1173-1176.
10. Martin J, Ginsberg RJ, Venkatraman ES, Bains MS, Downey RJ, Korst RJ, Kris MG, Risch VW. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 2002;20:1989-1995.
11. Keresztes RS, Prot JL, Pasmantier MW, Korst RJ, Altorki NK. Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin. J Thorac Cardiovasc Surg 2003;126:1603-1608.
12. Casper ES, Bajorin D. Phase II trial of carboplatin in patients with advanced melanoma. Invest New Drugs 1990;8:187-190.
13. Suzuki K, Usami T, Sudoko H, Ohtawara Y, Tajima A, Kawabe K, Aso Y. Experimental study on carboplatin toxicity - a comparison with cisplatin. Gan T Kagaku Ryoho 1988;15:2153-2158.
14. Watanabe W, Kuwabara R, Nakahara T, Hamasaki O, Sakamoto I, Okada K, Minamoto A, Mishima HK. Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas. Graefes Arch Clin Exp Opthalmol 2002;240:1033-1035.
15. Kai S, Kohmura H, Ishikawa K, Makihara Y, Ohta S, Kawano S, Takahashi N. Teratogenic effects of carboplatin, an oncostatic drug, administered during the early organogenetic period in rats. J Toxicol Sci 1989;14:115-130.
16. Ferrandina G, Distefano M, Testa A, De Vincenzo R, Scambia G. Management of an advanced ovarian cancer at 15 weeks of gestation: Case report and literature review. Gynecol Oncol 2005;97:693-696.
17. Adolph A, Le T, Khan K, Biem S. Recurrent metastatic fallopian tube carcinoma in pregnancy. Gynecol Oncol 2001;81:110-112.
18. Hoekstra AV, Keh P, Lurain JR. Placental site trophoblastic tumor: A review of 7 cases and their implications for prognosis and treatment. J Reprod Med 2004;49:447-452.
19. Nandakumaran M, Gardey C, Challier JC, Panigel M, Olive G. Transfer of salbutamol in the human placenta in vitro. Dev Pharmacol Ther 1981;3:88-98.
20. Nandakumaran M, Makhseed M, al-Rayyes S, al-Yatama M, Devarajan L, Sugathan T. Kinetics of palmitic acid transport in insulin-dependent diabetic pregnancies: In vitro study. Pediatr Int 2000;42:296-301.
21. Nandakumaran M, Makhseed M, Al-Rayyes S, Akanji AO, Sugathan TN. Effect of insulin on transport kinetics of alpha-aminoisobutyric acid in the perfused human placental lobule in vitro. Pediatr Int 2001;43:581-586.
22. Schneider H, Proegler M, Sodha R, Dancis J. Asymmetrical transfer of alpha-aminoisobutyric acid (AIB), leucine and lysine across the in vitro perfused human placenta. Placenta 1985;8:141-151.
23. Nandakumaran M, Sugathan TN. Assessment of transport dynamics in the perfused human placental lobule. Med Princ Pract 1992-93;3:219-222.
24. El-Yazigi A, Al-Saleh I. Rapid determination of platinum in plasma by flameless atomic absorption spectrophotometry following the administration of cisplatin to cancer patients. Ther Drug Monit 1986;8:318-320.
25. Brodie BB, Axelrod J, Soberman R. The estimation of antipyrine in biological materials. J Biol Chem 1949;179:25-29.
26. Rey E, Nandakumaran M, Richard MO, Loose JP, D'Athis P, Saint Maurice C, Olive G. Pharmacokinetics of flunitrazepam after single rectal administration in children. Dev Pharmacol Ther 1984;7(Suppl 1):206-212.
27. Nandakumaran M, Eldeen AS. Transfer of cyclosporine A in the perfused human placenta. Dev Pharmacol Ther 1990;15:101-105.
28. Challier JC, Guerre-Millo M, Richard MO, Schneider H, Panigel M, Olive G. Transfert et echange d'antipyrine dans le lobule placentaire humain perfuse in vitro. Ann Biol Anim Biochim Biophys 1977;17:1107-1115.
29. Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am J Obstet Gynecol 1972;114:822-828.
30. Battaglia FC, Meschia G, Makowski EL. Comparison of in vitro and in vivo placental permeability measurements. Am J Physiol 1969;216:1590-1594.
31. Seeds AE, Schruefer JJ, Reinhardt JA, Garlid KD. Diffusion mechanism across human placental tissue. Gynecol Invest 1973;4:31-37.
32. Koc ON, McFee M, Reed E, Gerson SL. Detection of platinum-DNA adducts in cord blood lymphocytes following in utero platinum exposure. Eur J Cancer 1994;30A:716-717.
33. Moya F, Thorndike V. Passage of drugs across the placenta. Am J Obstet Gynecol 1962;84:1778-1798.
34. Nandakumaran M, Challier JC, Rey E, Richard MO, Olive G. In vitro transfer of six benzamides in the human placenta. Dev Pharmacol Ther 1984;7:60-66.
35. Nandakumaran M, Olive G. Placental transfer of drugs: A mini-review. In: Roy Chowdhury NN, Roy Chowdhury J, editors. Recent trends in perinatology. Calcutta, India: Nachiketa; 1983. pp 141-178.
36. Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 2000;82:966-972.
37. Kumagai T, Inoue T, Mihara Y, Ebina K, Yokota K. Influence of drugs on the oxygen uptake rate and biosorption of activated sludge. Biol Pharm Bull 2006;29:183-186.
38. Boisdron-Celle M, Lebouil A, Gamelin E. Pharmacokinetic properties of platinum derivatives. Bull Cancer 2001;88:14-19.
39. Nandakumaran M, Gardey C, Challier JC, Rey E, Lambrey B, Olive G. Transfer of salbutamol, ritodrine and norepinephrine in the human placenta. In: Mathieu H, Olive G, Pontonnier H, editors. Pharmacologie du developpement. Vol. 86. Paris: INSERM, Paris; 1979. pp 255-264.
40. Ferrandina G, Distefano M, Testa A, De Vincenzo R, Scambia G. Management of an advanced ovarian cancer at 15 weeks gestation: Case report and literature review. Gynecol Oncol 2005;97:693-696.
41. Mendez LE, Mueller A, Salom E, Gonzalez-Quintero VH. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer. Gynecol Oncol 2003;102:1200-1202.
42. Shamkhani H, Anderson LM, Henderson CE, Moskal TJ, Runowicz CD, Dove LF, Jones AB, Cahney SG, Rice JM, Poirier MC. DNA adducts in human and patas monkey maternal and fetal tissues induced by platinum drug chemotherapy. Reprod Toxicol 1994;8:207-216.
43. Mulvihill A, Budning A, Jay V, Vandenhoven C, Heon E, Gallie BL, Chan HS. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol 2005;123:128-129.
44. Vadhan-Raj S, Kudelka AP, Garrison L, Gano J, Edwards CL, Freedman RS, Cavanagh JJ. Effects of interleukin-1 on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 1994;12:707-714.
45. Kearns CM, Egorin MJ. Considerations regarding the lessthan-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 1997;24:S291-296.
46. Reed I, Jacob J. Carboplatin and renal dysfunction. Ann Intern Med 1989;110:409-412.